Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

The recent approval of lenacapavir could change the way that clinicians approach both treating and preventing HIV in those at risk, as long as the treatment can get into their hands.

Although largely as expected by investors, BMO Capital says lenacapavir’s approval for prevention, now known as Yeztugo, marks “a major win for Gilead (GILD)” in driving meaningful growth in ...

Gilead and its partners' efforts to distribute generic lenacapavir could be derailed by cuts in international aid budgets ...

The US Food and Drug Administration (FDA) has approved lenacapavir , an injectable drug that offers long-lasting protection against HIV infection. Ad ...

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking studies, Gilead Sciences’ shot, a drug named lenacapavir, nearly ...

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One looming question: Will it be affordable for lower resource countries?

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking studies, Gilead Sciences’ shot, a drug named lenacapavir, nearly ...

Lenacapavir's six-month protection makes it the longest-lasting type, an option that could attract people wary of more frequent doctor visits or stigma from daily pills.